Pharma Leaders Ipsen and Ionis Post Strong 2026 Earnings and Expansion Plans

French drugmaker Ipsen reported first‑half 2026 sales of €2.19 billion, a 20% increase year‑on‑year, and lifted its core operating margin to 38.6%. The company upgraded its 2026 sales growth guidance to above 20% and announced the acquisition of Kartos Therapeutics for $450 million upfront with up to $1.3 billion in milestones, adding the navtemadlin program to its portfolio.

U.S. biotech Ionis Pharmaceuticals posted a 56% rise in second‑quarter 2026 revenue, driven by the recent launch of TRYNGOLZA, the first therapy to lower triglycerides and reduce pancreatitis risk in severe hypertriglyceridaemia patients. The company also highlighted progression of its Angelman‑syndrome trial, upcoming approvals for zilganersen and pelacarsen, and a global launch plan for bepirovirsen for chronic hepatitis B.